Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Harmony Biosciences Holdings ( (HRMY) ) just unveiled an update.
On June 11, 2025, Harmony Biosciences announced new preclinical data for BP1.15205, a promising orexin 2 receptor agonist, showing significant wake-promoting and cataplexy-suppressing effects in narcolepsy type 1 mouse models. The company plans to begin human trials in the latter half of 2025, with results expected in 2026, potentially enhancing its position in the sleep-wake disorder treatment market.
The most recent analyst rating on (HRMY) stock is a Sell with a $32.00 price target. To see the full list of analyst forecasts on Harmony Biosciences Holdings stock, see the HRMY Stock Forecast page.
Spark’s Take on HRMY Stock
According to Spark, TipRanks’ AI Analyst, HRMY is a Outperform.
Harmony Biosciences Holdings is performing strongly across multiple dimensions. The most significant factors are its robust financial performance and positive earnings call, which highlight strong growth, profitability, and a healthy pipeline. Technical indicators support a positive trend, while the fair valuation and positive corporate events further bolster the stock’s outlook. The combination of these factors results in a solid overall stock score.
To see Spark’s full report on HRMY stock, click here.
More about Harmony Biosciences Holdings
Harmony Biosciences is a pharmaceutical company focused on developing and commercializing innovative therapies for patients with rare neurological diseases. Established in 2017 by Paragon Biosciences, the company is headquartered in Plymouth Meeting, Pennsylvania.
Average Trading Volume: 703,701
Technical Sentiment Signal: Buy
Current Market Cap: $2.06B
Learn more about HRMY stock on TipRanks’ Stock Analysis page.